The potential role of nanomedicine in lung diseases
Main Article Content
Abstract
Nanomedicine is a rapidly emerging interdisciplinary field in which medicine is coupled with nanotechnology tools and techniques for advanced therapy with the aid of molecular knowledge. Nanoscale drug delivery systems provide a platform to improve the pharmacokinetics and increase the bio-distribution of therapeutic agents to target organs, thereby resulting in improved efficacy while limiting drug toxicity. These systems have revolutionized drug delivery approaches and are exploited for therapeutic purposes to carry the drug in the body in a controlled manner from the site of administration to the therapeutic target. Several promising molecular targets that have been identified as potential therapies for acute and chronic respiratory conditions have been limited because of difficulty with delivery systems. In particular, delivery of peptides, proteins, miRNAs to the lung is an ongoing challenge. Hence, it is an attractive strategy to test potential targets by employing a nanotechnology approach. Nanobiotechnology and nanoscience can provide innovative techniques to deliver drugs targeted to the site of inflamed organs. Here we review some of the nanomedicine approaches that have been proposed and studied over the last decade to facilitate the delivery of therapeutic agents specifically for acute and chronic lung diseases. Development of nano-sized carriers including nanoparticles, or liposomes holds great potential for diagnosis and advanced delivery systems for immunomodulation in respiratory diseases; however translational studies are urgently needed to validate the use of nanotechnology for clinical applications.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
Barbier F, Andremont A, Wolff M, Boua-dma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and manage-ment. Curr Opin Pulm Med. 2013;19:216-28.[PubMed: 23524477]
Barrecheguren M, Bourbeau J. Self-management strategies in chronic obstruc-tive pulmonary disease: a first step toward personalized medicine. Curr Opin Pulm Med. 2018; 24:191-198. [PubMed:29278544]
Boyle AJ, Mac Sweeney R, McAuley DF. Pharmacological treatments in ARDS; a state-of-the-art update. BMC Med. 2013;11:166-170.[PubMed:3957905]
Boyle AJ, McNamee JJ, McAuley DF. Bio-logical therapies in the acute respiratory distress syndrome. Expert Opin Biol Ther. 2014;14:969-981.[PubMed: 24702248]
da Silva AL, Cruz FF, Rocco PRM, Mo-rales MM. New perspectives in nanothera-peutics for chronic respiratory diseases. Biophys Rev. 2017;9:793-803.[PubMed: 28914424]
Chen X, Huang W, Wong BC, Yin L, Wong YF, Xu M, Yang Z. Liposomes pro-long the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomedicine. 2012;7:1139-1148.[PubMed: 22412300]
Dua K, Bebawy M, Awasthi R, Tekade RK, Tekade M, Gupta G, De Jesus Andreoli Pinto T, Hansbro PM. Chitosan and Its Derivatives in Nanocarrier Based Pulmo-nary Drug Delivery Systems. Pharm Nano-technol. 2017; doi: 10.2174/2211738505666170808095258. [Epub ahead of print] [PubMed: 28786352]
Geilich BM, Webster TJ. Reduced adhe-sion of Staphylococcus aureus to ZnO/PVC nanocomposites. Int J Nanomedicine. 2013; 8:1177-1184. [PubMed: 23658484]
Kaviratna AS, Banerjee R. Nanovesicle aerosols as surfactant therapy in lung in-jury. Nanomedicine. 2012;8:665-72.[PubMed: 21889480]
Kolanjiyil AV, Kleinstreuer C, Sadikot RT. Computationally efficient analysis of par-ticle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application. Comput Biol Med. 2017;84:247-253.[PubMed: 27836120]
Kollef MH. Ventilator-associated tracheo-bronchitis and ventilator-associated pneu-monia: truth vs myth. Chest. 2013;144(1):3-5.[PubMed: 23880669]
Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine. 2005;1:193-212.[PubMed: 17292079]
Lanza GM, Jenkins J, Schmieder AH, Mol-dobaeva A, Cui G, Zhang H, Yang X, Zhong Q, Keupp J, Sergin I, Paranandi KS, Eldridge L, Allen JS, Williams T, Scott MJ, Razani B, Wagner EM. Anti-angiogenic Nanotherapy Inhibits Airway Remodeling and Hyper-responsiveness of Dust Mite Triggered Asthma in the Brown Norway Rat. Theranostics. 2017;7(2):377-389.[PubMed: 28042341]
Lim SB, Rubinstein I, Sadikot RT, Artwohl JE, Önyüksel H. A novel peptide nanome-dicine against acute lung injury: GLP-1 in phospholipid micelles. Pharm Res. 2011;28:662-72.[PubMed: 21108040]
Lin EH, Chang HY, Yeh SD, Yang KY, Hu HS, Wu CW. Polyethyleneimine and DNA nanoparticles-based gene therapy for acute lung injury. Nanomedicine. 2013;9:1293-303.[PubMed: 23727098]
Löndahl J, Jakobsson JK, Broday DM, Aal-tonen HL, Wollmer P. Do nanoparticles provide a new opportunity for diagnosis of distal airspace disease? Int J Nanomedi-cine. 2016;12:41-51.[PubMed: 28053522]
Maurice NM, Bedi B, Sadikot RT. Pseu-domonas aeruginosa Biofilms: Host Re-sponse and Clinical Implications in Lung Infections. Am J Respir Cell Mol Biol. 2018; doi: 10.1165/rcmb.2017-0321TR. [Epub ahead of print] [PubMed: 29372812]
Merchant Z, Buckton G, Taylor KM, Stap-leton P, Saleem IY, Zariwala MG, Somavarapu S. A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections. Curr Pharm Des. 2016;22:2577-2598. [PubMed: 26983671]
Park HS, Kim KH, Jang S, Park JW, Cha HR, Lee JE, Kim JO, Kim SY, Lee CS, Kim JP, Jung SS. Attenuation of allergic airway inflammation and hyperresponsive-ness in a murine model of asthma by silver nanoparticles. Int J Nanomedicine. 2010;5:505-15. [PubMed: 20957173]
Puckett SD, Taylor E, Raimondo T, Web-ster TJ. The relationship between the nano-structure of titanium surfaces and bacterial attachment. Biomaterials. 2010;31:706-13.[PubMed: 19879645]
Ratemi E, Sultana Shaik A, Al Faraj A, Halwani R. Alternative approaches for the treatment of airway diseases: focus on na-noparticle medicine. Clin Exp Allergy. 2016;46(8):1033-1042. [PubMed: 27404025]
Sadikot RT, Rubinstein I. Long-acting, multi-targeted nanomedicine: addressing unmet medical need in acute lung injury. J Biomed Nanotechnol. 2009;5:614-619.[PubMed: 20201223]
Sadikot RT, Christman JW, Blackwell TS. Molecular targets for modulating lung in-flammation and injury. Curr Drug Targets. 2004;5:581-588. [PubMed: 15270205]
Sadikot RT. The potential role of nano- and micro-technology in the management of critical illnesses. Adv Drug Deliv Rev. 2014;77:27-31.[PubMed: 25204519]
Taylor E, Webster TJ. Reducing infections through nanotechnology and nanoparticles. Int J Nanomedicine. 2011;6:1463-1473.[PubMed: 21796248]
Thorley AJ, Tetley TD. New perspectives in nanomedicine. Pharmacol Ther. 2013;140:176-185.[PubMed: 23811125]
Tran N, Mir A, Mallik D, Sinha A, Nayar S, Webster TJ. Bactericidal effect of iron oxide nanoparticles on Staphylococcus aureus. Int J Nanomedicine. 2010; 5:277-83. [PubMed: 20463943]
Tran PA, Webster TJ. Selenium nanopar-ticles inhibit Staphylococcus aureus growth. Int J Nanomedicine. 2011;6: 1553-1558.[PubMed: 21845045]
van Rijt SH, Bein T, Meiners S. Medical nanoparticles for next generation drug delivery to the lungs. Eur Respir J. 2014; 44: 765-774. [PubMed: 24791828]
Verissimo NC, Geilich BM, Oliveira HG, Caram R, Webster TJ. Reducing Staphylo-coccus aureus growth on Ti alloy nano-structured surfaces through the addition of Sn. J Biomed Mater Res A. 2015;103: 3757-3763.[PubMed: 26033413]
Villar J, Sulemanji D, Kacmarek RM. The acute respiratory distress syndrome: inci-dence and mortality, has it changed?Curr Opin Crit Care. 2014;20:3-9.[PubMed: 24309954]
Vij N, Min T, Bodas M, Gorde A, Roy I. Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseas-es. Nanomedicine. 2016;12:2415-2427. [PubMed: 27381067]
Wang W, Zhu R, Xie Q, Li A, Xiao Y, Li K, Liu H, Cui D, Chen Y, Wang S.Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine. 2012;7:3667-3677.[PubMed: 22888226]
Willis L, Hayes D Jr, Mansour HM. Thera-peutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung. 2012;190:251-262.[PubMed: 24376349]
Xiao X, Zeng X, Zhang X, Ma L, Liu X, Yu H, Mei L, Liu Z. Effects of Caryota mitis profilin-loaded PLGA nanoparticles in a murine model of allergic asthma. Int J Nanomedicine. 2013;8:4553-4562.[PubMed: 24376349]
Yuan Z, Syed M, Panchal D, Joo M, Bedi C, Lim S, Onyuksel H, Rubinstein I, Co-lonna M, Sadikot RT. TREM-1-accentuated lung injury via miR-155 is inhibited by LP17 nanomedicine. Am J Physiol Lung Cell Mol Physiol. 2016;310:L426-438.[PubMed: 26684249]